Loxo Oncology competitive analysis

Latest publications and patents of Loxo Oncology New

Explore the latest publications and patents granted to Loxo Oncology, showcasing their recent innovations and technological advancements.

Last updated on: Sep 29, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Loxo Oncology

Jul 24, 2024Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-CarboxamideGranted And Under Opposition

Explore Loxo Oncology's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jul 24, 2024Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide1

Latest PTAB cases involving Loxo Oncology

Discover the latest PTAB cases involving Loxo Oncology, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Loxo Oncology with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
LOXO ONCOLOGY - 1 - - Non-Active
SYNTHON3216 - - Highly Aggressive